Pharmaceutical business to enter new markets thanks to acquisition

Leeds-based Rosemont Pharmaceuticals has acquired Lucis Pharma Ltd, a specialist pharmaceutical business in Gloucestershire.

It means Rosemont, which is backed by Inflexion private equity, will be able to expand its existing portfolio and gain access to a pipeline of innovative products providing lifesaving pharmaceuticals to the UK and overseas markets.

Founded in 2012, Lucis is a provider in the development and licensing of novel and exclusive medicines.

It has established a strong portfolio which, in addition to a pipeline of new developments, serves a growing patient need for liquid medicines. 

The acquisition will enable Rosemont to enter the unit dose/sachet market through the pipeline products, while growing the business through recent Lucis product launches in 2021/22.

Howard Taylor, chief executive officer of Rosemont, said: “As well as continuing to broaden our portfolio and add to our strong growth globally, this acquisition also gives access to pipeline products and developer relationships to accelerate our entry into new product areas such as sachets.

“We will continue creating innovative solutions that meet the needs of dysphagic patients and establish best practice for their care.”

Rosemont has over 50 years of experience in novel and oral liquid medicines.

Its range of products features over 130 oral liquid medicines addressing a variety of therapeutic areas such as cardiac health, endocrinology, and pain management for patients with swallowing difficulties. 

At its production facility in Leeds, the business manufactures more than one million litres of bulk liquid, equating to four million bottles of liquid medicines per year.